CVS

CVS Health's stock experienced several notable events in the past six months. In Q1 2026, the company reported strong earnings, surpassing expectations and raising its full-year adjusted EPS guidance, leading to a stock price surge. CVS Health consistently pays quarterly dividends. The stock experienced a decline due to regulatory scrutiny surrounding pharmacy benefit managers (PBMs) and a proposed class action lawsuit. CVS Health reported an increase in total revenues for Q4 and full-year 2025. At its Investor Day 2025, CVS Health updated its financial guidance and committed to a mid-teens Adjusted EPS compound annual growth rate through 2028. The acquisition of Rite Aid assets positively impacted prescription volume and revenue in Q1 2026.